Brind.

Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.

Steady: 0 in the last 7 days Updated sep 26

The latest in this situation

  1. The $12B acquisition of Avidity assets by Novartis triggers calls for board shake-up.
  2. Novartis continues development of medicines related to Avidity.

How it started

7 reports, 6 independent, last reported Sep 11. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 6 independent outlets

Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.

Who's involved

What this event is mainly about
AvidityNovartisEli Lilly and Company

How it developed

Newest first. Tap a step to see who reported it.
  1. Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sub-event
  2. Novartis is actively pursuing Avidity Biosciences in an acquisition attempt.1 source
  3. Novartis completed the acquisition of Avidity for $12 billion.1 source
  4. Avidity and Novartis are involved in a major corporate action following acquisition interest.1 source
  5. Novartis completed the acquisition of Avidity Biosciences, which was previously under acquisition interest.1 source
  6. Avidity partners with Eli Lilly and is targeted for acquisition by Novartis.1 source
  7. FDA granted Breakthrough Therapy designation to Avidity's DMD drug as Novartis pursues acquisition.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • yahoo.com
  • 933thedrive.com
  • yahoo.com
  • morningstar.com
  • ZacksRNA Stock Moves More Than 30% in a Week: What's Driving This Rally? Shares of Avidity Biosciences RNA have soared 36% in the past month, all thanks to a report issued by the Financial Times (FT), whi
  • Investing.comAvidity Biosciences stock soars on Novartis takeover approach report Investing.com -- Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmac
  • Insider MonkeyAvidity (RNA) Gets 26% Jump on Potential Takeover We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Av